Meiji Co., Ltd.

Meiji Milk Products Company, Limited

Meiji Dairies Corporation

Akinori Kume

Kohsuke Kino

Kazuo Dairiki

Toshio Sone

Katsunori Kimura

Hiroshi Tsuboi

Akina Satou

Noriko Kaneko

Akiko Iwama

The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level. Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels,OLL2922, were found.

Lactic acid bacterium having effect of lowering blood uric acid level

A peptide-based immunotherapeutic agent effective for every allergy patient is provided. A reagent for typing HLA class II molecules of the patient to be used in selecting a peptide-based immunotherapeutic agent effective for every allergy patient is also provided. The peptide-based immunotherapeutic agent enables the optimal peptide-based immunotherapy for each patient, so that a marked improvement in peptide-immunotherapy can be expected. The peptide-based immunotherapeutic agent is also effective for patients who cannot be treated by peptide-based immunotherapy using major antigen peptide recognized in a particular patient population. Furthermore, the peptide-based immunotherapeutic agent enables simple and easy typing of HLA class II molecules of allergy patients.

Peptide-based immunotherapeutic agent

The present invention provides a monomolecular multi-epitope peptide prepared by binding T cell epitope regions derived from different allergen molecules with each other. A peptide-based immunotherapeutic agent containing an effective amount of the multi-epitope peptide can treat a wide range of allergic diseases.

Peptide-based immunotherapeutic agent for treating allergic diseases

Growing community of inventors

Kanagawa, Japan

Akinori Kume